Jafron BiomedicalLtd 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Fan Dong

최고 경영자

CN¥3.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	14.2yrs
CEO 소유권	45.9%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO

Fan Dong (54 yo)

14.2yrs

테뉴어

CN¥3,741,000

보상

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...

리더십 팀

이름	위치	테뉴어	보상	소유권
Fan Dong	Chairman of Board of Directors & GM	no data	CN¥3.74m	45.86% CN¥ 10.9b
Xueyun Liao	Director & Financial Director	1.6yrs	CN¥500.50k	0.019% CN¥ 4.5m
De Zhi Li	Deputy General Manager	no data	CN¥865.40k	0.46% CN¥ 108.4m
Xian Min Tang	Deputy GM & Director	no data	CN¥2.65m	2.76% CN¥ 653.1m
Aijun Wu	Deputy General Manager	4.5yrs	CN¥2.44m	0.031% CN¥ 7.4m
Rui Wang	General Manager	1.2yrs	CN¥510.40k	데이터 없음
Cong Huang	Board Secretary	2.2yrs	CN¥455.20k	0.00044% CN¥ 104.3k

1.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: 300529 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fan Dong	Chairman of Board of Directors & GM	14.2yrs	CN¥3.74m	45.86% CN¥ 10.9b
Xueyun Liao	Director & Financial Director	less than a year	CN¥500.50k	0.019% CN¥ 4.5m
Xian Min Tang	Deputy GM & Director	14.2yrs	CN¥2.65m	2.76% CN¥ 653.1m
Claudio Ronco	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음
Feng Li	Non-Independent Director	4.6yrs	CN¥1.08m	0.099% CN¥ 23.4m
Xiaohong Peng	Chairman of Supervisory Board	4.6yrs	데이터 없음	데이터 없음
Wen Lei	Non-Independent Director	4.6yrs	CN¥177.20k	데이터 없음
Rinaldo Bellomo	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음
Thomas Rimmelé	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음
John Prowle	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음
Antoine Schneider	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음
Olivier Joannes-Boyau	Member of Global Advisory Board	3.4yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 300529 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Jafron BiomedicalLtd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.18 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Jafron Biomedical Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Dividend reduced to CN¥0.40

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 18%

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings released: EPS: CN¥1.12 (vs CN¥1.49 in FY 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings released: EPS: CN¥1.49 (vs CN¥1.10 in FY 2020)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥90.54

New 90-day high: CN¥84.63

New 90-day low: CN¥63.65

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day high: CN¥78.75

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

New 90-day high - CN¥77.44

Earnings released

Jafron Biomedical Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령